Physician profile
William Bartek
NPI 1598722522
$284,358.04
in general payments reported to CMS, 2019-2025
26 companies · $7,060 in 2025
The $7,060 reported for 2025 was more than what 94% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $978 · 2021: $45K · 2022: $106K · 2023: $78K · 2024: $46K · 2025: $7,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $98K · Travel and Lodging: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $6,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $98,186.77 |
| Travel and Lodging | $17,909.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $6,757.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $281,455.67 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Ethicon INC. | $1,032.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.74 | 2020-2025 | Ofev |
| Glaxosmithkline, LLC. | $291.33 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $188.51 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| United Therapeutics Corporation | $148.53 | 2023-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $124.06 | 2023-2024 | Arikayce |
| Verona Pharma, INC. | $72.30 | 2025 | Ohtuvayre |
| Electromed, INC. | $71.60 | 2022-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $50.43 | 2023 | Acthar |
| Regeneron Healthcare Solutions, INC. | $49.87 | 2025 | Dupixent |
| Advanced Respiratory, INC | $48.31 | 2021 | |
| Sunovion Pharmaceuticals INC. | $39.00 | 2019 | |
| Genzyme Corporation | $31.22 | 2025 | |
| Mylan Specialty L.P. | $27.56 | 2023 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $27.43 | 2023 | Inogen |
| Grifols USA, LLC | $26.56 | 2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $26.42 | 2024 | Veltassa |
| Viatris Specialty LLC | $25.43 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $25.40 | 2024 | Glassia |
| Ani Pharmaceuticals, INC. | $21.56 | 2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $19.69 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.40 | 2019 | |
| Olympus America INC. | $18.97 | 2023 | High Definition Lcd Monitor |
| 3b Medical, INC. | $18.87 | 2025 | Luna |
| Inspire Medical Systems, INC. | $17.59 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bartek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.